Lan Z, Ahmad N, Baghaei P, et al. - Researchers investigated the absolute and relative frequency of adverse events linked with different tuberculosis drugs in order to inscribe valuable information for clinicians and tuberculosis programs in selecting optimal treatment regimens. A meta-analysis was performed employing individual-level patient data gathered from studies that inscribed adverse events resulting in permanent discontinuation of anti-tuberculosis medications. They identified 58 studies; of these, 50 studies were from the updated individual patient data meta-analysis for multidrug-resistant tuberculosis treatment. The analysis was done on 35 of these studies, with 9,178 patients. The lowest incidence of adverse events leading to permanent drug discontinuation was observed in correlation to providing fluoroquinolones, clofazimine, and bedaquiline, whereas the highest incidence was observed in correlation with second-line injectable drugs, aminosalicylic acid, and linezolid. Findings thereby suggest the significance of close monitoring of adverse events for patients being treated for multidrug-resistant tuberculosis. Further, the findings highlight the urgent necessity for safer and better-tolerated drugs to annihilate morbidity from treatment itself for patients with multidrug-resistant tuberculosis.